4.7 Article

Daprodustat: A potential game-changer in renal anemia therapy-A perspective

期刊

FRONTIERS IN PHARMACOLOGY
卷 14, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2023.1249492

关键词

anemia; chronic kidney disease; daprodustat; HIF; renal disease

向作者/读者索取更多资源

The FDA has approved daprodustat as the first oral treatment option for anemia in CKD dialysis patients. Clinical trials have shown its efficacy and safety, non-inferior to darbepoetin and potentially reducing IV iron usage. Daprodustat also holds potential for treating anemia in non-dialysis patients with CKD and for patients with both renal anemia and heart failure, pending further research.
The United States FDA has approved daprodustat (DPD) as the first oral treatment option for anemia due to chronic kidney disease (CKD) in dialysis patients. Clinical trials have demonstrated DPD's efficacy and safety, showing non-inferiority to darbepoetin and suggesting reduced IV iron usage. DPD also holds potential for treating chronic kidney disease anemia in non-dialysis patients and may have benefits for patients with coexisting renal anemia and heart failure, pending further research and trials.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据